Teva Pharmaceutical Industries Ltd (TEVA.N)

TEVA.N on New York Stock Exchange

50.85USD
17 Apr 2014
Price Change (% chg)

$0.94 (+1.88%)
Prev Close
$49.91
Open
$50.14
Day's High
$50.96
Day's Low
$50.05
Volume
582,521
Avg. Vol
939,818
52-wk High
$54.69
52-wk Low
$36.26

TEVA.N

Chart for TEVA.N

About

Teva Pharmaceutical Industries Ltd (Teva) is an Israel-based pharmaceutical and drug company. It develops, produces and markets generic drugs in all treatment categories. The Company has a pharmaceutical business, whose principal products include Copaxone and Azilect. Teva’s active pharmaceutical ingredient (API) business... (more)

Overall

Beta: 0.68
Market Cap (Mil.): $47,379.96
Shares Outstanding (Mil.): 949.73
Dividend: 0.34
Yield (%): 2.51

Financials

  TEVA.N Industry Sector
P/E (TTM): 34.07 33.26 33.35
EPS (TTM): 1.49 -- --
ROI: 3.54 19.66 18.92
ROE: 5.60 20.35 19.68
Search Stocks

Supreme Court denies Teva stay in Copaxone patent fight

WASHINGTON - U.S. Supreme Court Chief Justice John Roberts on Friday denied a request by Teva Pharmaceutical Industries Ltd to stay a lower-court ruling in a patent case that favored the developers of generic versions of Teva's top-selling multiple sclerosis drug.

2:19am IST

UPDATE 1-U.S. top court denies Teva stay in Copaxone patent fight

WASHINGTON, April 18 - U.S. Supreme Court Chief Justice John Roberts on Friday denied a request by Teva Pharmaceutical Industries Ltd to stay a lower-court ruling in a patent case that favored the developers of generic versions of Teva's top-selling multiple sclerosis drug.

1:58am IST

U.S. top court denies Teva stay in Copaxone patent fight

WASHINGTON, April 18 - U.S. Supreme Court Chief Justice John Roberts on Friday denied a request by Teva Pharmaceutical Industries Ltd that would have prevented a lower court ruling from going into effect while the court considers an appeal in a patent fight over Teva's top-selling multiple sclerosis drug Copaxone.

1:33am IST

UPDATE 1-Teva willing to post bond to suspend decision on Copaxone

WASHINGTON, April 17 - Teva Pharmaceutical Industries Ltd on Thursday told the U.S. Supreme Court that it is willing to post up to a $500 million bond in return for a decision suspending a lower court ruling that would allow generic competitors to go on the market as soon as next month.

18 Apr 2014

Teva willing to post $500 million bond in Copaxone case

WASHINGTON, April 17 - Teva Pharmaceutical Industries Ltd on Thursday told the U.S. Supreme Court that it is willing to post up to a $500 million bond in return for a decision suspending a lower court ruling that would allow generic competitors to go on the market as soon as next month.

18 Apr 2014

UPDATE 2-Teva settles patent suit with Pfizer over Celebrex

April 17 - Teva Pharmaceutical Industries Ltd signed a deal that allows the Israeli drugmaker to launch a generic version of Pfizer Inc's blockbuster painkiller Celebrex in December.

17 Apr 2014

Teva, Pfizer settle patent lawsuit over blockbuster painkiller

- Teva Pharmaceutical Industries Ltd said it settled a patent lawsuit with Pfizer Inc, allowing the Israeli drugmaker to launch a generic version of Pfizer's blockbuster painkiller Celebrex in December.

17 Apr 2014

Teva, Pfizer settle patent lawsuit over painkiller Celebrex

April 17 - Teva Pharmaceutical Industries Ltd said it settled a patent litigation with Pfizer Inc, allowing the Israeli drugmaker to launch a generic version of Pfizer's blockbuster pain medication, Celebrex, in December.

17 Apr 2014

Generics file response to Teva in Copaxone patent fight

WASHINGTON - Generic drug manufacturers on Monday asked the U.S. Supreme Court to allow a lower court ruling favoring them to take effect while the high court considers an appeal in a patent fight over Teva Pharmaceutical Industries Ltd's top-selling multiple sclerosis drug, Copaxone.

15 Apr 2014

Generics file response to Teva in Copaxone patent fight

WASHINGTON, April 14 - Generic drug manufacturers on Monday asked the U.S. Supreme Court to allow a lower court ruling favoring them to take effect while the high court considers an appeal in a patent fight over Teva Pharmaceutical Industries Ltd's top-selling multiple sclerosis drug, Copaxone.

15 Apr 2014

Competitors

  Price Change
Novartis AG (NOVN.VX) CHF74.70 +0.35
Biogen Idec Inc (BIIB.OQ) $290.54 -0.94

Earnings vs. Estimates

Search Stocks